{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:27:56Z","timestamp":1775028476678,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of higher education in Anhui province","award":["2022AH050760"],"award-info":[{"award-number":["2022AH050760"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-024-02289-5","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T09:02:45Z","timestamp":1726477365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lipid levels and multiple myeloma risk: insights from Meta-analysis and mendelian randomization"],"prefix":"10.1186","volume":"23","author":[{"given":"Weiwei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Charwudzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianfang","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"2289_CR1","doi-asserted-by":"crossref","unstructured":"Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024.","DOI":"10.3324\/haematol.2023.284662"},{"issue":"4","key":"2289_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313.","journal-title":"N Engl J Med"},{"issue":"7","key":"2289_CR3","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1007\/s10238-023-01174-2","volume":"23","author":"R Torcasio","year":"2023","unstructured":"Torcasio R, Gallo Cantafio ME, Ikeda RK, Ganino L, Viglietto G, Amodio N. Lipid metabolic vulnerabilities of multiple myeloma. Clin Exp Med. 2023;23(7):3373\u201390.","journal-title":"Clin Exp Med"},{"issue":"23","key":"2289_CR4","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1111\/bph.15653","volume":"178","author":"G Xu","year":"2021","unstructured":"Xu G, Huang S, Peng J, Gao X, Li M, Yu S, et al. Targeting lipid metabolism in multiple myeloma cells: rational development of a synergistic strategy with proteasome inhibitors. Br J Pharmacol. 2021;178(23):4741\u201357.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"2289_CR5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1182\/blood.2021013832","volume":"139","author":"C Panaroni","year":"2022","unstructured":"Panaroni C, Fulzele K, Mori T, Siu KT, Onyewadume C, Maebius A, et al. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. Blood. 2022;139(6):876\u201388.","journal-title":"Blood"},{"key":"2289_CR6","doi-asserted-by":"publisher","first-page":"925807","DOI":"10.3389\/fonc.2022.925807","volume":"12","author":"DN Petrusca","year":"2022","unstructured":"Petrusca DN, Lee KP, Galson DL. Role of sphingolipids in multiple myeloma progression, Drug Resistance, and their potential as therapeutic targets. Front Oncol. 2022;12:925807.","journal-title":"Front Oncol"},{"key":"2289_CR7","doi-asserted-by":"crossref","unstructured":"Choi T, Choi IY, Han K, Jeong SM, Yoo JE, Rhee SY et al. Lipid level, lipid variability, and risk of multiple myeloma: a Nationwide Population-based study of 3,527,776 subjects. Cancers (Basel). 2021;13(3).","DOI":"10.3390\/cancers13030540"},{"issue":"7","key":"2289_CR8","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.1016\/j.clml.2020.02.011","volume":"20","author":"B Ponvilawan","year":"2020","unstructured":"Ponvilawan B, Charoenngam N, Rittiphairoj T, Ungprasert P. Receipt of Statins is Associated with Lower Risk of multiple myeloma: systematic review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2020;20(7):e399\u2013413.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2289_CR9","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00277-020-04157-5","volume":"99","author":"P Zhang","year":"2020","unstructured":"Zhang P, Liu B. Statin use and the risk of multiple myeloma: a PRISMA-compliant meta-analysis. Ann Hematol. 2020;99(8):1805\u201312.","journal-title":"Ann Hematol"},{"issue":"6","key":"2289_CR10","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/ije\/dyx207","volume":"46","author":"VM Walker","year":"2017","unstructured":"Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. Int J Epidemiol. 2017;46(6):2078\u201389.","journal-title":"Int J Epidemiol"},{"issue":"42","key":"2289_CR11","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1093\/eurheartj\/ehac394","volume":"43","author":"BJ Arsenault","year":"2022","unstructured":"Arsenault BJ. From the garden to the clinic: how mendelian randomization is shaping up atherosclerotic cardiovascular disease prevention strategies. Eur Heart J. 2022;43(42):4447\u20139.","journal-title":"Eur Heart J"},{"issue":"10","key":"2289_CR12","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/ijc.34214","volume":"151","author":"Q Wang","year":"2022","unstructured":"Wang Q, Shi Q, Lu J, Wang Z, Hou J. Causal relationships between inflammatory factors and multiple myeloma: a bidirectional mendelian randomization study. Int J Cancer. 2022;151(10):1750\u20139.","journal-title":"Int J Cancer"},{"issue":"1","key":"2289_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s12916-023-03086-0","volume":"21","author":"Q Wang","year":"2023","unstructured":"Wang Q, Shi Q, Wang Z, Lu J, Hou J. Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma. BMC Med. 2023;21(1):377.","journal-title":"BMC Med"},{"issue":"10","key":"2289_CR14","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1182\/bloodadvances.2020001502","volume":"4","author":"M Went","year":"2020","unstructured":"Went M, Cornish AJ, Law PJ, Kinnersley B, van Duin M, Weinhold N, et al. Search for multiple myeloma risk factors using mendelian randomization. Blood Adv. 2020;4(10):2172\u20139.","journal-title":"Blood Adv"},{"issue":"4","key":"2289_CR15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00277-021-04451-w","volume":"100","author":"L Hu","year":"2021","unstructured":"Hu L, Charwudzi A, Li Q, Zhu W, Tao Q, Xiong S, et al. Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R\/R B-ALL patients: a systematic review and meta-analysis. Ann Hematol. 2021;100(4):1003\u201312.","journal-title":"Ann Hematol"},{"issue":"11","key":"2289_CR16","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ng.2797","volume":"45","author":"CJ Willer","year":"2013","unstructured":"Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274\u201383.","journal-title":"Nat Genet"},{"issue":"8","key":"2289_CR17","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41588-021-00892-1","volume":"53","author":"AR Barton","year":"2021","unstructured":"Barton AR, Sherman MA, Mukamel RE, Loh PR. Whole-exome imputation within UK Biobank powers rare coding variant association and fine-mapping analyses. Nat Genet. 2021;53(8):1260\u20139.","journal-title":"Nat Genet"},{"key":"2289_CR18","doi-asserted-by":"publisher","first-page":"104543","DOI":"10.1016\/j.ebiom.2023.104543","volume":"90","author":"Z Li","year":"2023","unstructured":"Li Z, Zhang B, Liu Q, Tao Z, Ding L, Guo B, et al. Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease. EBioMedicine. 2023;90:104543.","journal-title":"EBioMedicine"},{"issue":"22","key":"2289_CR19","doi-asserted-by":"publisher","first-page":"20964","DOI":"10.1002\/cam4.6649","volume":"12","author":"L Li","year":"2023","unstructured":"Li L, Yu Z, Ren J, Niu T. Low cholesterol levels are associated with increasing risk of plasma cell neoplasm: a UK biobank cohort study. Cancer Med. 2023;12(22):20964\u201375.","journal-title":"Cancer Med"},{"issue":"1","key":"2289_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10552-017-0991-y","volume":"29","author":"GC Kabat","year":"2018","unstructured":"Kabat GC, Kim MY, Chlebowski RT, Vitolins MZ, Wassertheil-Smoller S, Rohan TE. Serum lipids and risk of obesity-related cancers in postmenopausal women. Cancer Causes Control. 2018;29(1):13\u201324.","journal-title":"Cancer Causes Control"},{"issue":"10","key":"2289_CR21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00277-012-1489-z","volume":"91","author":"G Nagel","year":"2012","unstructured":"Nagel G, Stocks T, Spath D, Hjartaker A, Lindkvist B, Hallmans G, et al. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann Hematol. 2012;91(10):1519\u201331.","journal-title":"Ann Hematol"},{"issue":"1","key":"2289_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-020-00963-6","volume":"13","author":"KM Pedersen","year":"2020","unstructured":"Pedersen KM, Colak Y, Bojesen SE, Nordestgaard BG. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals. J Hematol Oncol. 2020;13(1):129.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2289_CR23","doi-asserted-by":"publisher","first-page":"18818","DOI":"10.1038\/s41598-023-45801-0","volume":"13","author":"J Ren","year":"2023","unstructured":"Ren J, Wu M. Causal effects of genetically determined blood metabolites on multiple myeloma: a mendelian randomization study. Sci Rep. 2023;13(1):18818.","journal-title":"Sci Rep"},{"key":"2289_CR24","doi-asserted-by":"publisher","first-page":"100974","DOI":"10.1016\/j.neo.2024.100974","volume":"50","author":"X Zhou","year":"2024","unstructured":"Zhou X, He R, Hu WX, Luo S, Hu J. Targeting myeloma metabolism: how abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors. Neoplasia. 2024;50:100974.","journal-title":"Neoplasia"},{"issue":"7","key":"2289_CR25","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/liv.15575","volume":"43","author":"TO Faquih","year":"2023","unstructured":"Faquih TO, van Klinken JB, Li-Gao R, Noordam R, van Heemst D, Boone S, et al. Hepatic triglyceride content is intricately associated with numerous metabolites and biochemical pathways. Liver Int. 2023;43(7):1458\u201372.","journal-title":"Liver Int"},{"issue":"2","key":"2289_CR26","doi-asserted-by":"publisher","first-page":"100494","DOI":"10.1016\/j.jlr.2023.100494","volume":"65","author":"MJ Chapman","year":"2024","unstructured":"Chapman MJ, Orsoni A, Mellett NA, Nguyen A, Robillard P, Shaw JE, et al. Pitavastatin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia. J Lipid Res. 2024;65(2):100494.","journal-title":"J Lipid Res"},{"issue":"4","key":"2289_CR27","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","volume":"163","author":"DA Culver","year":"2023","unstructured":"Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, et al. Efzofitimod for the treatment of pulmonary sarcoidosis. Chest. 2023;163(4):881\u201390.","journal-title":"Chest"},{"issue":"12","key":"2289_CR28","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.2174\/1568026623666230522103321","volume":"23","author":"R Irshad","year":"2023","unstructured":"Irshad R, Tabassum S, Husain M. Aberrant lipid metabolism in Cancer: current status and emerging therapeutic perspectives. Curr Top Med Chem. 2023;23(12):1090\u2013103.","journal-title":"Curr Top Med Chem"},{"key":"2289_CR29","doi-asserted-by":"crossref","unstructured":"Liu X, Xu P, Wang L, Zhang C, Wang M, Ouyang J et al. Cholesterol Levels Provide Prognostic Information in patients with multiple myeloma. Clin Lab. 2020;66(4).","DOI":"10.7754\/Clin.Lab.2019.190824"},{"key":"2289_CR30","doi-asserted-by":"publisher","first-page":"1157969","DOI":"10.3389\/fendo.2023.1157969","volume":"14","author":"L Bao","year":"2023","unstructured":"Bao L, Wang YT, Lu MQ, Chu B, Shi L, Gao S, et al. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis. Front Endocrinol (Lausanne). 2023;14:1157969.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2289_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.athplu.2023.09.003","volume":"54","author":"A Makris","year":"2023","unstructured":"Makris A, Pagkali A, Nikolousis E, Filippatos TD, Agouridis AP. High-density lipoprotein cholesterol and multiple myeloma: a systematic review and meta-analysis. Atheroscler Plus. 2023;54:7\u201313.","journal-title":"Atheroscler Plus"},{"issue":"2\u20133","key":"2289_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejphar.2011.09.031","volume":"670","author":"YS Tu","year":"2011","unstructured":"Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB, Guan YY. Involvement of Chk1-Cdc25A-cyclin A\/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur J Pharmacol. 2011;670(2\u20133):356\u201364.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2289_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/carcin\/bgi036","volume":"26","author":"P Cafforio","year":"2005","unstructured":"Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005;26(5):883\u201391.","journal-title":"Carcinogenesis"},{"issue":"3","key":"2289_CR34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2174\/138161206775201974","volume":"12","author":"NW van de Donk","year":"2006","unstructured":"van de Donk NW, Bloem AC, van der Spek E, Lokhorst HM. New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway. Curr Pharm Des. 2006;12(3):327\u201340.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"2289_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12967-023-04165-9","volume":"21","author":"Y Gu","year":"2023","unstructured":"Gu Y, Jin Q, Hu J, Wang X, Yu W, Wang Z, et al. Causality of genetically determined metabolites and metabolic pathways on osteoarthritis: a two-sample mendelian randomization study. J Transl Med. 2023;21(1):357.","journal-title":"J Transl Med"},{"issue":"17","key":"2289_CR36","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-12-2917","volume":"19","author":"L Puchades-Carrasco","year":"2013","unstructured":"Puchades-Carrasco L, Lecumberri R, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Prosper F, et al. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. Clin Cancer Res. 2013;19(17):4770\u20139.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2289_CR37","first-page":"1369","volume":"44","author":"QL Huang","year":"2022","unstructured":"Huang QL, Zhao RR, Yang BY, Jiang RY, Yang LL, Yan S, et al. [Preliminary exploration of the metabolic profile and metabolic pathways in newly diagnosed multiple myeloma]. Zhonghua Zhong Liu Za Zhi. 2022;44(12):1369\u201375.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2289_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.molimm.2017.08.010","volume":"90","author":"S Schellenburg","year":"2017","unstructured":"Schellenburg S, Schulz A, Poitz DM, Muders MH. Role of neuropilin-2 in the immune system. Mol Immunol. 2017;90:239\u201344.","journal-title":"Mol Immunol"},{"key":"2289_CR39","doi-asserted-by":"crossref","unstructured":"Lungulescu C, Ghimpau V, Gheonea DI, Sur D, Lungulescu CV. The role of Neuropilin-2 in the epithelial to mesenchymal transition of Colorectal Cancer: a systematic review. Biomedicines. 2022;10(1).","DOI":"10.3390\/biomedicines10010172"},{"issue":"694","key":"2289_CR40","doi-asserted-by":"publisher","first-page":"eade5855","DOI":"10.1126\/scitranslmed.ade5855","volume":"15","author":"M Wang","year":"2023","unstructured":"Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, et al. Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Sci Transl Med. 2023;15(694):eade5855.","journal-title":"Sci Transl Med"},{"issue":"9","key":"2289_CR41","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2003-10-3527","volume":"103","author":"K Podar","year":"2004","unstructured":"Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. 2004;103(9):3474\u20139.","journal-title":"Blood"},{"key":"2289_CR42","doi-asserted-by":"crossref","unstructured":"Ria R, Melaccio A, Racanelli V, Vacca A. Anti-VEGF drugs in the treatment of multiple myeloma patients. J Clin Med. 2020;9(6).","DOI":"10.3390\/jcm9061765"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-024-02289-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:39:30Z","timestamp":1726745970000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-024-02289-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2289"],"URL":"https:\/\/doi.org\/10.1186\/s12944-024-02289-5","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}